Tumor resistance to antimesothelin CAR- T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope

Despite many clinical trials, CAR - T cells are not yet approved for human solid tumor therapy. One popular target is mesothelin (MSLN) which is highly expressed on the surface of about 30% of cancers including mesothelioma and cancers of the ovary, pancreas, and lung. MSLN is shed by proteases that cleave near the C terminus, leaving a short peptide attached to the cell. Most anti-MSLN antibodies bind to shed MSLN, which can prevent their binding to target cells. To overcome this limitation, we developed an antibody (15B6) that binds next to the membrane at the protease- sensitive region, does not bind to shed MSLN, and makes CAR - T cells that have much higher antitumor activity than a CAR - T that binds to shed MSLN. We have now humanized the Fv (h15B6), so the CAR - T can be used to treat patients and show that h15B6 CAR - T produces complete regressions in a hard - to - treat pancreatic cancer patient derived xenograft model, whereas CAR - T targeting a shed epitope (SS1) have no antitumor activity. In these pancreatic cancers, the h15B6 CAR - T replicates and replaces the cancer cells, whereas there are no CAR - T cells in the tumors receiving SS1 CAR - T. To determine the mechanism accounting for high activity, we used an OVCAR-8 intraperitoneal model to show that poorly active SS1-CAR-T cells are bound to shed MSLN, whereas highly active h15B6 CAR - T do not contain bound MSLN enabling them to bind to and kill cancer cells.